𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

✍ Scribed by A. Takeda; E. Loveman; A. Clegg; J. Kirby; J. Picot; E. Payne; C. Green

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
115 KB
Volume
21
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

The use of cholinesterase inhibiors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clintical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process.

Objective

To provide a systematic review of the best quality evidence of the effects of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately‐severe AD.

Design

Electronic databases were searched, references of all retrieved articles were checked, and experts were contacted for advice, peer review and to identify additional references. Randomised controlled trials (RCTs) were included if they fulfilled pre‐specified criteria. Data were synthesised through a narrative review.

Results

Twenty‐six RCTs that compared any one of the cholinesterase inhibitors with either a control group or with another cholinesterase inhibitor were included. The quality of reporting and methodology was varied. Treatment with donepezil, rivastigmine or galantamine resulted in significantly better cognitive performance using the ADAS‐cog scale when compared with placebo. These findings were generally supported using the MMSE scale. Results from head to head comparisons were limited by the low number of studies and the study quality; generally showing no robust support for any one drug. Few studies evaluated quality of life. Adverse events were generally related to the gastrointestinal system, with a tendency for these to be more common in the treatment arms.

Conclusions

The cholinesterase inhibitors donepezil, rivastigmine, and galantamine can delay cognitive impairment in patients with mild to moderately‐severe AD for at least 6 months duration. Copyright © 2005 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

A comparison of donepezil and galantamin
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis
✍ Robin D. J. Harry; Konstantine K. Zakzanis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

This review was conducted in order to determine the efficacy of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease, and also to determine whether galantamine was a superior pharmacological intervention. Meta-analytic methods were used to analyse the data from eig

Review of donepezil, rivastigmine, galan
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
✍ V. P. Prasher 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

A systematic review of the effects of ph
A systematic review of the effects of physical activity on physical functioning, quality of life and depression in older people with dementia
✍ Rachel Potter; David Ellard; Karen Rees; Margaret Thorogood 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB 👁 2 views

## Abstract ## Background Depression is common in older people with dementia. Physical activity is effective in reducing depression in adults but there is limited evidence about its effectiveness in people with dementia. ## Design and Methods A systematic review and partial meta‐analysis of phys

What do we know about quality of life in
What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia
✍ Sube Banerjee; Kritika Samsi; Charles D. Petrie; Jose Alvir; Michael Treglia; El 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## Objective Given its complexity, there is growing consensus on the need to measure patient‐rated broad outcomes like health‐related quality of life (HRQL) as well as discrete functions like cognition and behaviour in dementia. This review brings together current data on the distribut